Positive data at the annual meeting of the American Society of Clinical Oncology (ASCO) will help boost chances for Sanofi’s (Euronext: SAN) isatuximab in a looming head-to-head with Johnson & Johnson’s (NYSE: JNJ) Darzalex (daratumumab).
The two anti-CD38 compounds are being developed in multiple myeloma, and both firms have data for their options at the event.
As well as offering a new patient-friendly subcutaneous formulation, J&J is showing off more positive Phase III data for its 2015-approved option at ASCO this year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze